GE Healthcare Technologies Inc banner

GE Healthcare Technologies Inc
F:L0T

Watchlist Manager
GE Healthcare Technologies Inc Logo
GE Healthcare Technologies Inc
F:L0T
Watchlist
Price: 57.8 EUR 2.77% Market Closed
Market Cap: €26.4B

Wall St Price Targets

L0T Price Targets Summary
GE Healthcare Technologies Inc

Wall Street analysts forecast L0T stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for L0T is 78.45 EUR with a low forecast of 62.52 EUR and a high forecast of 98 EUR.

Lowest Forecast
Price Target
62.52 EUR
8% Upside
Average Forecast
Price Target
78.45 EUR
36% Upside
Highest Forecast
Price Target
98 EUR
70% Upside
GE Healthcare Technologies Inc Competitors:
Price Targets

Revenue
Forecast

4% / Year
Past Growth
5% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
4% / Year
Past Growth
5% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Over the last 5 years, the compound annual growth rate for Revenue has been 4%. The projected CAGR for the next 7 years is 5%.

Gross Profit
Forecast

4% / Year
Past Growth
6% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss
4% / Year
Past Growth
6% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Over the last 5 years, the compound annual growth rate for Gross Profit has been 4%. The projected CAGR for the next 7 years is 6%.

Operating Income
Forecast

0% / Year
Past Growth
9% / Year
Estimated Growth
Estimates Accuracy
-13%
Average Miss
0% / Year
Past Growth
9% / Year
Estimated Growth
Estimates Accuracy
-13%
Average Miss

Over the last 5 years, the compound annual growth rate for Operating Income has been 0%. The projected CAGR for the next 7 years is 9%.

Pre-Tax Income
Forecast

0% / Year
Past Growth
9% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
0% / Year
Past Growth
9% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Over the last 5 years, the compound annual growth rate for Pre-Tax Income has been 0%. The projected CAGR for the next 3 years is 9%.

Net Income
Forecast

-32% / Year
Past Growth
9% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
-32% / Year
Past Growth
9% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 5 years, the compound annual growth rate for Net Income has been -32%. The projected CAGR for the next 7 years is 9%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is L0T's stock price target?
Price Target
78.45 EUR

According to Wall Street analysts, the average 1-year price target for L0T is 78.45 EUR with a low forecast of 62.52 EUR and a high forecast of 98 EUR.

What is the Revenue forecast for GE Healthcare Technologies Inc?
Projected CAGR
5%

Over the last 5 years, the compound annual growth rate for Revenue has been 4%. The projected CAGR for the next 7 years is 5%.

What is the Gross Profit forecast for GE Healthcare Technologies Inc?
Projected CAGR
6%

Over the last 5 years, the compound annual growth rate for Gross Profit has been 4%. The projected CAGR for the next 7 years is 6%.

What is the Operating Income forecast for GE Healthcare Technologies Inc?
Projected CAGR
9%

Over the last 5 years, the compound annual growth rate for Operating Income has been 0%. The projected CAGR for the next 7 years is 9%.

What is the Pre-Tax Income forecast for GE Healthcare Technologies Inc?
Projected CAGR
9%

Over the last 5 years, the compound annual growth rate for Pre-Tax Income has been 0%. The projected CAGR for the next 3 years is 9%.

What is the Net Income forecast for GE Healthcare Technologies Inc?
Projected CAGR
9%

Over the last 5 years, the compound annual growth rate for Net Income has been -32%. The projected CAGR for the next 7 years is 9%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett